285 related articles for article (PubMed ID: 33388477)
1. Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target.
Le X; Negrao MV; Reuben A; Federico L; Diao L; McGrail D; Nilsson M; Robichaux J; Munoz IG; Patel S; Elamin Y; Fan YH; Lee WC; Parra E; Solis Soto LM; Chen R; Li J; Karpinets T; Khairullah R; Kadara H; Behrens C; Sepesi B; Wang R; Zhu M; Wang L; Vaporciyan A; Roth J; Swisher S; Haymaker C; Zhang J; Wang J; Wong KK; Byers LA; Bernatchez C; Zhang J; Wistuba II; Gibbons DL; Akbay EA; Heymach JV
J Thorac Oncol; 2021 Apr; 16(4):583-600. PubMed ID: 33388477
[TBL] [Abstract][Full Text] [Related]
2. Predictive value of CD73 expression for the efficacy of immune checkpoint inhibitors in NSCLC.
Ishii H; Azuma K; Kawahara A; Kinoshita T; Matsuo N; Naito Y; Tokito T; Yamada K; Akiba J; Hoshino T
Thorac Cancer; 2020 Apr; 11(4):950-955. PubMed ID: 32061060
[TBL] [Abstract][Full Text] [Related]
3. YAP1 as a Novel Negative Biomarker of Immune Checkpoint Inhibitors for EGFR-Mutant Non-Small-Cell Lung Cancer.
Li LC; Chen XW; Fang L; Jian CL; Yu YX; Liao XY; Sun JG
Can Respir J; 2023; 2023():4689004. PubMed ID: 37388902
[TBL] [Abstract][Full Text] [Related]
4. The regulation of CD73 in non-small cell lung cancer.
Han Y; Lee T; He Y; Raman R; Irizarry A; Martin ML; Giaccone G
Eur J Cancer; 2022 Jul; 170():91-102. PubMed ID: 35598361
[TBL] [Abstract][Full Text] [Related]
5. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
[No Abstract] [Full Text] [Related]
6. Anti-PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC.
Tu E; McGlinchey K; Wang J; Martin P; Ching SL; Floc'h N; Kurasawa J; Starrett JH; Lazdun Y; Wetzel L; Nuttall B; Ng FS; Coffman KT; Smith PD; Politi K; Cooper ZA; Streicher K
JCI Insight; 2022 Feb; 7(3):. PubMed ID: 35132961
[TBL] [Abstract][Full Text] [Related]
7. EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer.
Hastings K; Yu HA; Wei W; Sanchez-Vega F; DeVeaux M; Choi J; Rizvi H; Lisberg A; Truini A; Lydon CA; Liu Z; Henick BS; Wurtz A; Cai G; Plodkowski AJ; Long NM; Halpenny DF; Killam J; Oliva I; Schultz N; Riely GJ; Arcila ME; Ladanyi M; Zelterman D; Herbst RS; Goldberg SB; Awad MM; Garon EB; Gettinger S; Hellmann MD; Politi K
Ann Oncol; 2019 Aug; 30(8):1311-1320. PubMed ID: 31086949
[TBL] [Abstract][Full Text] [Related]
8. Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations.
Lin A; Wei T; Meng H; Luo P; Zhang J
Mol Cancer; 2019 Sep; 18(1):139. PubMed ID: 31526368
[TBL] [Abstract][Full Text] [Related]
9. Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma.
Yang L; He YT; Dong S; Wei XW; Chen ZH; Zhang B; Chen WD; Yang XR; Wang F; Shang XM; Zhong WZ; Wu YL; Zhou Q
J Immunother Cancer; 2022 Jan; 10(2):. PubMed ID: 35140113
[TBL] [Abstract][Full Text] [Related]
10. Targeting Immunometabolism Mediated by CD73 Pathway in
Passarelli A; Aieta M; Sgambato A; Gridelli C
Front Immunol; 2020; 11():1479. PubMed ID: 32760402
[TBL] [Abstract][Full Text] [Related]
11. Targeting CD73 to Overcomes Resistance to First-Generation EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.
Kim M; Kim S; Yim J; Keam B; Kim TM; Jeon YK; Kim DW; Heo DS
Cancer Res Treat; 2023 Oct; 55(4):1134-1143. PubMed ID: 37218137
[TBL] [Abstract][Full Text] [Related]
12. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
13. Tumor intrinsic and extrinsic functions of CD73 and the adenosine pathway in lung cancer.
Kowash RR; Akbay EA
Front Immunol; 2023; 14():1130358. PubMed ID: 37033953
[TBL] [Abstract][Full Text] [Related]
14. [Immune Microenvironment Comparation Study between EGFR Mutant and EGFR Wild Type Lung Adenocarcinoma Patients Based on TCGA Database].
Zhu G; Li Y; Shi R; Xu S; Zhang Z; Cao P; Chen C; Liu H; Chen J
Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):236-244. PubMed ID: 33910272
[TBL] [Abstract][Full Text] [Related]
15. Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma.
Stewart EL; Mascaux C; Pham NA; Sakashita S; Sykes J; Kim L; Yanagawa N; Allo G; Ishizawa K; Wang D; Zhu CQ; Li M; Ng C; Liu N; Pintilie M; Martin P; John T; Jurisica I; Leighl NB; Neel BG; Waddell TK; Shepherd FA; Liu G; Tsao MS
J Clin Oncol; 2015 Aug; 33(22):2472-80. PubMed ID: 26124487
[TBL] [Abstract][Full Text] [Related]
16. ARID1A deficiency reverses the response to anti-PD(L)1 therapy in EGFR-mutant lung adenocarcinoma by enhancing autophagy-inhibited type I interferon production.
Sun D; Qian H; Wang J; Xie T; Teng F; Li J; Xing P
Cell Commun Signal; 2022 Oct; 20(1):156. PubMed ID: 36229854
[TBL] [Abstract][Full Text] [Related]
17. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
Hsu PC; Jablons DM; Yang CT; You L
Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387256
[TBL] [Abstract][Full Text] [Related]
18. IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC.
Patel SA; Nilsson MB; Yang Y; Le X; Tran HT; Elamin YY; Yu X; Zhang F; Poteete A; Ren X; Shen L; Wang J; Moghaddam SJ; Cascone T; Curran M; Gibbons DL; Heymach JV
Clin Cancer Res; 2023 Apr; 29(7):1292-1304. PubMed ID: 36595561
[TBL] [Abstract][Full Text] [Related]
19. Epidermal Growth Factor Receptor Mutations in Resectable Non-Small Cell Lung Cancer Patients and their Potential Role in the Immune Landscape.
Xia W; Mao W; Chen R; Lu R; Liu F; He Y; Wang S; Li X; Zheng M
Med Sci Monit; 2019 Nov; 25():8764-8776. PubMed ID: 31746315
[TBL] [Abstract][Full Text] [Related]
20. [Application of Immune Checkpoint Inhibitors in EGFR Mutant
Advanced Non-small Cell Lung Cancer].
Zheng Y; Jiang W; Li J; Dai L; Chen D; Li Y; Huang L; Wang M
Zhongguo Fei Ai Za Zhi; 2022 Sep; 25(9):671-677. PubMed ID: 36172732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
